RESUMEN
Paeonol has a wide range of pharmacological activities. It is mainly used to protect cardiovascular and cerebrovascular system, promote microcirculation, antibacterial and anti-inflammatory, antitumor, anti-oxidation, anti-allergic reaction, enhance immunity, and treat diabetic osteoporosis, etc. In recent years, it not only improves the method of artificially synthesizing paeonol, but also carries out a large number of structural modification and transformation of paeonol. Five major parts, carbonyl, phenolic hydroxyl, carbonyl α-H, methoxy, and benzene rings, have been mainly modified. About 16 kinds of paeonol derivatives were produced including carboxylic acid esters, sulfonates esters, phosphates esters, ethers, NO donors, glycosidation, paeonol sodium, Schiff bases, thiazoles, oximes, hydroxyalkylation, α,β-unsaturated ketones, aminomethylation, α-H halogenation, demethylation, and benzene ring halogenation. In this paper, the derivatives of paeonol and their pharmacological activities were reviewed in combination with the literatures on paeonol derivatives at home and abroad. This article may provide basis for further study of this type of compound.
RESUMEN
<p><b>OBJECTIVE</b>To study the cost-effectiveness, benefit and utility of infant hepatitis B vaccination in Shanghai from 1992 to 2001.</p><p><b>METHODS</b>To calculate the cost of hepatitis B vaccination by cost analysis method. Both the numbers of persons with HBsAg positive and patient with hepatitis B, cirrhosis and liver cancer decreased as the index of direct effect. To study the sick-time and the cost of treating hepatitis B, cirrhosis and liver cancer patients, a face to face questionnaire was used and quasi method was adopted to understand the effect of cure and the course of hepatitis B. The cost benefit analysis method was also used to calculate the cost benefit of HBV vaccine. The disability adjusted life years (DALY) was regarded as an index of utility to measure the disease burden.</p><p><b>RESULTS</b>Input of 501,129.49 Yuan might have the result of reducing one liver cancer patient, ten cirrhosis patients, one hundred chronic hepatitis B patients and one thousand HBsAg positive people. The cost of hepatitis B vaccination was 0.24 hundred million Yuan during the past ten years in Shanghai, which had obtained the total benefit value of 41.22 hundred million Yuan, with a cost benefit ratio of 1:172 Yuan. It was estimated that the total disease burden of hepatitis B, cirrhosis and liver cancer patients was 59,762.55 DALY in order to reduce one DALY loss cost of 402.50 Yuan.</p><p><b>CONCLUSION</b>HBV vaccine inoculation in infants seemed to be a low-cost input and high-effect output strategy.</p>